LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 11

Search options

  1. Article ; Online: Stereoselective ketamine effect on cardiac output: a population pharmacokinetic/pharmacodynamic modelling study in healthy volunteers.

    Kamp, Jasper / van Velzen, Monique / Aarts, Leon / Niesters, Marieke / Dahan, Albert / Olofsen, Erik

    British journal of anaesthesia

    2021  Volume 127, Issue 1, Page(s) 23–31

    Abstract: Background: Ketamine has cardiac excitatory side-effects. Currently, data on the effects of ketamine and metabolite concentrations on cardiac output are scarce. We therefore developed a pharmacodynamic model derived from data from a randomised clinical ... ...

    Abstract Background: Ketamine has cardiac excitatory side-effects. Currently, data on the effects of ketamine and metabolite concentrations on cardiac output are scarce. We therefore developed a pharmacodynamic model derived from data from a randomised clinical trial. The current study is part of a larger clinical study evaluating the potential mitigating effect of sodium nitroprusside on the psychedelic effects of ketamine.
    Methods: Twenty healthy male subjects received escalating esketamine and racemic ketamine doses in combination with either placebo or sodium nitroprusside on four visits: (i) esketamine and placebo, (ii) esketamine and sodium nitroprusside, (iii) racemic ketamine and placebo, and (iv) racemic ketamine and sodium nitroprusside. During each visit, arterial blood samples were obtained and cardiac output was measured. Nonlinear mixed-effect modelling was used to analyse the cardiac output time-series data. Ketamine metabolites were added to the model in a sequential manner to evaluate the effects of metabolites.
    Results: A model including an S-ketamine and S-norketamine effect best described the data. Ketamine increased cardiac output, whereas modelling revealed that S-norketamine decreased cardiac output. No significant effects were detected for R-ketamine, metabolites other than S-norketamine, or sodium nitroprusside on cardiac output.
    Conclusions: S-Ketamine, but not R-ketamine, increased cardiac output in a dose-dependent manner. In contrast to S-ketamine, its metabolite S-norketamine reduced cardiac excitation in a dose-dependent manner.
    Clinical trial registration: Dutch Cochrane Center 5359.
    MeSH term(s) Adult ; Anesthetics, Dissociative/chemistry ; Anesthetics, Dissociative/pharmacokinetics ; Cardiac Output/drug effects ; Cardiac Output/physiology ; Cross-Over Studies ; Dose-Response Relationship, Drug ; Double-Blind Method ; Healthy Volunteers ; Humans ; Ketamine/chemistry ; Ketamine/pharmacokinetics ; Male ; Stereoisomerism ; Young Adult
    Chemical Substances Anesthetics, Dissociative ; Ketamine (690G0D6V8H)
    Language English
    Publishing date 2021-04-22
    Publishing country England
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 80074-0
    ISSN 1471-6771 ; 0007-0912
    ISSN (online) 1471-6771
    ISSN 0007-0912
    DOI 10.1016/j.bja.2021.02.034
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Ketamine Psychedelic and Antinociceptive Effects Are Connected.

    Olofsen, Erik / Kamp, Jasper / Henthorn, Thomas K / van Velzen, Monique / Niesters, Marieke / Sarton, Elise / Dahan, Albert

    Anesthesiology

    2022  Volume 136, Issue 5, Page(s) 792–801

    MeSH term(s) Analgesia ; Analgesics/pharmacology ; Hallucinogens/pharmacology ; Humans ; Ketamine ; Male ; Pain
    Chemical Substances Analgesics ; Hallucinogens ; Ketamine (690G0D6V8H)
    Language English
    Publishing date 2022-04-19
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 269-0
    ISSN 1528-1175 ; 0003-3022
    ISSN (online) 1528-1175
    ISSN 0003-3022
    DOI 10.1097/ALN.0000000000004176
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Ketamine Pharmacokinetics.

    Kamp, Jasper / Olofsen, Erik / Henthorn, Thomas K / van Velzen, Monique / Niesters, Marieke / Dahan, Albert

    Anesthesiology

    2020  Volume 133, Issue 6, Page(s) 1192–1213

    MeSH term(s) Adult ; Anesthetics, Dissociative/pharmacokinetics ; Child ; Humans ; Ketamine/pharmacokinetics
    Chemical Substances Anesthetics, Dissociative ; Ketamine (690G0D6V8H)
    Language English
    Publishing date 2020-09-30
    Publishing country United States
    Document type Journal Article ; Meta-Analysis ; Research Support, Non-U.S. Gov't ; Systematic Review
    ZDB-ID 269-0
    ISSN 1528-1175 ; 0003-3022
    ISSN (online) 1528-1175
    ISSN 0003-3022
    DOI 10.1097/ALN.0000000000003577
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Meltdose Tacrolimus Population Pharmacokinetics and Limited Sampling Strategy Evaluation in Elderly Kidney Transplant Recipients.

    Kamp, Jasper / Zwart, Tom C / Meziyerh, Soufian / van der Boog, Paul J M / Nijgh, Esther E / van Duin, Koen / de Vries, Aiko P J / Moes, Dirk Jan A R

    Pharmaceutics

    2023  Volume 16, Issue 1

    Abstract: Background: Meltdose tacrolimus (Envarsus: Methods: A total of 34 kidney transplant recipients aged ≥65 years, starting on meltdose tacrolimus directly after transplantation, were included. An eight-point whole blood AUC: Results: The PK data were ...

    Abstract Background: Meltdose tacrolimus (Envarsus
    Methods: A total of 34 kidney transplant recipients aged ≥65 years, starting on meltdose tacrolimus directly after transplantation, were included. An eight-point whole blood AUC
    Results: The PK data were best described using a two-compartment model, including three transit compartments and a mixture model for oral absorption. The best three-sample LSS was T = 0, 2, 6 h. The best four-sample LSSs were T = 0, 2, 6, 8 h and T = 0, 1, 6, 8 h.
    Conclusions: The developed population PK model adequately described the tacrolimus PK data in a population of elderly kidney transplant recipients. In addition, the developed population PK model and LSS showed an adequate estimation of tacrolimus exposure, and may therefore be used to aid in tacrolimus dose individualization.
    Language English
    Publishing date 2023-12-21
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527217-2
    ISSN 1999-4923
    ISSN 1999-4923
    DOI 10.3390/pharmaceutics16010017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Pharmacokinetic and pharmacodynamic considerations for NMDA-receptor antagonist ketamine in the treatment of chronic neuropathic pain: an update of the most recent literature.

    Kamp, Jasper / Van Velzen, Monique / Olofsen, Erik / Boon, Martijn / Dahan, Albert / Niesters, Marieke

    Expert opinion on drug metabolism & toxicology

    2019  Volume 15, Issue 12, Page(s) 1033–1041

    Abstract: ... ...

    Abstract Introduction
    MeSH term(s) Analgesics/administration & dosage ; Analgesics/pharmacokinetics ; Analgesics/pharmacology ; Animals ; Chronic Pain/drug therapy ; Chronic Pain/physiopathology ; Excitatory Amino Acid Antagonists/administration & dosage ; Excitatory Amino Acid Antagonists/pharmacokinetics ; Excitatory Amino Acid Antagonists/pharmacology ; Humans ; Ketamine/administration & dosage ; Ketamine/pharmacokinetics ; Ketamine/pharmacology ; Neuralgia/drug therapy ; Neuralgia/physiopathology
    Chemical Substances Analgesics ; Excitatory Amino Acid Antagonists ; Ketamine (690G0D6V8H)
    Language English
    Publishing date 2019-11-13
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2214462-6
    ISSN 1744-7607 ; 1742-5255
    ISSN (online) 1744-7607
    ISSN 1742-5255
    DOI 10.1080/17425255.2019.1689958
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Pharmacokinetics of ketamine and its major metabolites norketamine, hydroxynorketamine, and dehydronorketamine: a model-based analysis.

    Kamp, Jasper / Jonkman, Kelly / van Velzen, Monique / Aarts, Leon / Niesters, Marieke / Dahan, Albert / Olofsen, Erik

    British journal of anaesthesia

    2020  Volume 125, Issue 5, Page(s) 750–761

    Abstract: Background: Recent studies show activity of ketamine metabolites, such as hydroxynorketamine, in producing rapid relief of depression-related symptoms and analgesia. To improve our understanding of the pharmacokinetics of ketamine and metabolites ... ...

    Abstract Background: Recent studies show activity of ketamine metabolites, such as hydroxynorketamine, in producing rapid relief of depression-related symptoms and analgesia. To improve our understanding of the pharmacokinetics of ketamine and metabolites norketamine, dehydronorketamine, and hydroxynorketamine, we developed a population pharmacokinetic model of ketamine and metabolites after i.v. administration of racemic ketamine and the S-isomer (esketamine). Pharmacokinetic data were derived from an RCT on the efficacy of sodium nitroprusside (SNP) in reducing the psychotomimetic side-effects of ketamine in human volunteers.
    Methods: Three increasing i.v. doses of esketamine and racemic ketamine were administered to 20 healthy volunteers, and arterial plasma samples were obtained for measurement of ketamine and metabolites. Subjects were randomised to receive esketamine/SNP, esketamine/placebo, racemic ketamine/SNP, and racemic ketamine/placebo on four separate occasions. The time-plasma concentration data of ketamine and metabolites were analysed using a population compartmental model approach.
    Results: The pharmacokinetics of ketamine and metabolites were adequately described by a seven-compartment model with two ketamine, norketamine, and hydroxynorketamine compartments and one dehydronorketamine compartment with metabolic compartments in-between ketamine and norketamine, and norketamine and dehydronorketamine main compartments. Significant differences were found between S- and R-ketamine enantiomer pharmacokinetics, with up to 50% lower clearances for the R-enantiomers, irrespective of formulation. Whilst SNP had a significant effect on ketamine clearances, simulations showed only minor effects of SNP on total ketamine pharmacokinetics.
    Conclusions: The model is of adequate quality for use in future pharmacokinetic and pharmacodynamic studies into the efficacy and side-effects of ketamine and metabolites.
    Clinical trial registration: Dutch Cochrane Center 5359.
    MeSH term(s) Adult ; Anesthetics, Dissociative/administration & dosage ; Anesthetics, Dissociative/pharmacokinetics ; Biotransformation ; Computer Simulation ; Cross-Over Studies ; Double-Blind Method ; Drug Compounding ; Female ; Humans ; Injections, Intravenous ; Ketamine/administration & dosage ; Ketamine/analogs & derivatives ; Ketamine/blood ; Ketamine/chemistry ; Ketamine/pharmacokinetics ; Male ; Models, Theoretical ; Nitroprusside/therapeutic use ; Postoperative Complications/prevention & control ; Postoperative Complications/psychology ; Stereoisomerism ; Young Adult
    Chemical Substances Anesthetics, Dissociative ; Nitroprusside (169D1260KM) ; Esketamine (50LFG02TXD) ; Ketamine (690G0D6V8H) ; norketamine (XQY6JVF94X)
    Language English
    Publishing date 2020-08-21
    Publishing country England
    Document type Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 80074-0
    ISSN 1471-6771 ; 0007-0912
    ISSN (online) 1471-6771
    ISSN 0007-0912
    DOI 10.1016/j.bja.2020.06.067
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine.

    Bahar, Muh Akbar / Kamp, Jasper / Borgsteede, Sander D / Hak, Eelko / Wilffert, Bob

    British journal of clinical pharmacology

    2018  Volume 84, Issue 12, Page(s) 2704–2715

    Abstract: Aim: Metoprolol (a CYP2D6 substrate) is often co-prescribed with paroxetine/fluoxetine (a CYP2D6 inhibitor) because the clinical relevance of this drug-drug interaction (DDI) is still unclear. This review aimed to systematically evaluate the available ... ...

    Abstract Aim: Metoprolol (a CYP2D6 substrate) is often co-prescribed with paroxetine/fluoxetine (a CYP2D6 inhibitor) because the clinical relevance of this drug-drug interaction (DDI) is still unclear. This review aimed to systematically evaluate the available evidence and quantify the clinical impact of the DDI.
    Method: Pubmed, Web of Science, Cochrane Library and Embase were searched for studies reporting on the effect of the DDI among adults published until April 2018. Data on pharmacokinetics, pharmacodynamics and clinical outcomes from experimental, observational and case report studies were retrieved. The protocol of this study was registered in PROSPERO (CRD42018093087).
    Results: We found nine eligible articles that consisted of four experimental and two observational studies as well as three case reports. Experimental studies reported that paroxetine increased the AUC of metoprolol three to five times, and significantly decreased systolic blood pressure and heart rate of patients. Case reports concerned bradycardia and atrioventricular block due to the DDI. Results from observational studies were conflicting. A cohort study indicated that the DDI was significantly associated with the incidence of early discontinuation of metoprolol as an indicator of the emergence of metoprolol-related side effects. In a case-control study, the DDI was not significantly associated with bradycardia.
    Conclusion: Despite the contradictory conclusions from the current literature, the majority of studies suggest that the DDI can lead to adverse clinical consequences. Since alternative antidepressants and beta-blockers with comparable efficacy are available, such DDIs can be avoided. Nonetheless, if prescribing the combination is unavoidable, a dose adjustment or close monitoring of the metoprolol-related side effects is necessary.
    MeSH term(s) Cytochrome P-450 CYP2D6/physiology ; Drug Interactions ; Drug Therapy, Combination ; Female ; Fluoxetine/administration & dosage ; Fluoxetine/pharmacology ; Humans ; Male ; Metoprolol/administration & dosage ; Metoprolol/adverse effects ; Metoprolol/pharmacokinetics ; Middle Aged ; Paroxetine/administration & dosage ; Paroxetine/pharmacology
    Chemical Substances Fluoxetine (01K63SUP8D) ; Paroxetine (41VRH5220H) ; Cytochrome P-450 CYP2D6 (EC 1.14.14.1) ; Metoprolol (GEB06NHM23)
    Language English
    Publishing date 2018-09-24
    Publishing country England
    Document type Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't ; Systematic Review
    ZDB-ID 188974-6
    ISSN 1365-2125 ; 0306-5251 ; 0264-3774
    ISSN (online) 1365-2125
    ISSN 0306-5251 ; 0264-3774
    DOI 10.1111/bcp.13741
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Opioid-induced respiratory depression in humans: a review of pharmacokinetic-pharmacodynamic modelling of reversal.

    Algera, Marijke Hyke / Kamp, Jasper / van der Schrier, Rutger / van Velzen, Monique / Niesters, Marieke / Aarts, Leon / Dahan, Albert / Olofsen, Erik

    British journal of anaesthesia

    2019  Volume 122, Issue 6, Page(s) e168–e179

    Abstract: Background: Opioids are potent painkillers but come with serious adverse effects ranging from addiction to potentially lethal respiratory depression. A variety of drugs with separate mechanisms of action are available to prevent or reverse opioid- ... ...

    Abstract Background: Opioids are potent painkillers but come with serious adverse effects ranging from addiction to potentially lethal respiratory depression. A variety of drugs with separate mechanisms of action are available to prevent or reverse opioid-induced respiratory depression (OIRD).
    Methods: The authors reviewed human studies on reversal of OIRD using models that describe and predict the time course of pharmacokinetics (PK) and pharmacodynamics (PD) of opioids and reversal agents and link PK to PD.
    Results: The PKPD models differ in their basic structure to capture the specific pharmacological mechanisms by which reversal agents interact with opioid effects on breathing. The effect of naloxone, a competitive opioid receptor antagonist, is described by the combined effect-compartment receptor-binding model to quantify rate limitation at the level of drug distribution and receptor kinetics. The effects of reversal agents that act through non-opioidergic pathways, such as ketamine and the experimental drug GAL021, are described by physiological models, in which stimulants act at CO
    Conclusions: Model-based drug development is needed to design an 'ideal' reversal agent-that is, one that is not influenced by opioid receptor kinetics, does not interfere with opioid analgesia, has a rapid onset of action with long-lasting effects, and is devoid of adverse effects.
    MeSH term(s) Analgesics, Opioid/adverse effects ; Analgesics, Opioid/antagonists & inhibitors ; Carotid Body/drug effects ; Doxapram/pharmacology ; Drug Design ; Humans ; Models, Biological ; Naloxone/pharmacology ; Narcotic Antagonists/pharmacology ; Respiratory Insufficiency/chemically induced ; Respiratory Insufficiency/prevention & control ; Triazines/pharmacology
    Chemical Substances Analgesics, Opioid ; Narcotic Antagonists ; Triazines ; Naloxone (36B82AMQ7N) ; GAL021 (4RZ4OGT40Z) ; Doxapram (94F3830Q73)
    Language English
    Publishing date 2019-02-01
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 80074-0
    ISSN 1471-6771 ; 0007-0912
    ISSN (online) 1471-6771
    ISSN 0007-0912
    DOI 10.1016/j.bja.2018.12.023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Pharmacokinetics of oral hydrocortisone - Results and implications from a randomized controlled trial.

    Werumeus Buning, Jorien / Touw, Daan J / Brummelman, Pauline / Dullaart, Robin P F / van den Berg, Gerrit / van der Klauw, Melanie M / Kamp, Jasper / Wolffenbuttel, Bruce H R / van Beek, André P

    Metabolism: clinical and experimental

    2017  Volume 71, Page(s) 7–16

    Abstract: Context and objective: This study aimed at comparing pharmacokinetics of two different doses of hydrocortisone (HC) in patients with secondary adrenal insufficiency (SAI).: Design, setting and patients: Forty-six patients with SAI participated in ... ...

    Abstract Context and objective: This study aimed at comparing pharmacokinetics of two different doses of hydrocortisone (HC) in patients with secondary adrenal insufficiency (SAI).
    Design, setting and patients: Forty-six patients with SAI participated in this randomized double-blind crossover study.
    Intervention: Patients received two different doses of HC (0.2-0.3mg HC/kg body weight/day and 0.4-0.6mg HC/kg body weight/day).
    Main outcome measures: One- and two-compartment population models for plasma free cortisol, plasma total cortisol and salivary cortisol were parameterized. The individual pharmacokinetic parameters clearance (CL), volume of distribution (V
    Results: The one-compartment models gave a better description of the data compared to the two-compartment models. Weight-adjusted dosing reduced variability in cortisol exposure with comparable AUCs between weight groups. However, there was large inter-individual variation in CL and V
    Conclusions: Cortisol concentrations after a doubling of the dose were only dose proportional for free cortisol. HC pharmacokinetics can differ up to 10-fold inter-individually and individual adjustment of treatment doses may be necessary. Doubling of the HC dose in fast metabolizers (patients that showed relative low AUC and thus high clearance compared to other patients), does not result in significantly enhanced exposure during large parts of the day and these patients may need other management strategies.
    MeSH term(s) Adrenal Insufficiency/metabolism ; Adult ; Aged ; Area Under Curve ; Cross-Over Studies ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Half-Life ; Hormone Replacement Therapy ; Humans ; Hydrocortisone/blood ; Hydrocortisone/metabolism ; Hydrocortisone/pharmacokinetics ; Male ; Middle Aged ; Saliva/metabolism ; Serum Albumin/analysis ; Transcortin/analysis ; Young Adult
    Chemical Substances Serum Albumin ; Transcortin (9010-38-2) ; Hydrocortisone (WI4X0X7BPJ)
    Language English
    Publishing date 2017-06
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 80230-x
    ISSN 1532-8600 ; 0026-0495
    ISSN (online) 1532-8600
    ISSN 0026-0495
    DOI 10.1016/j.metabol.2017.02.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis.

    Kamp, Jasper / Bolhuis, Mathieu S / Tiberi, Simon / Akkerman, Onno W / Centis, Rosella / de Lange, Wiel C / Kosterink, Jos G / van der Werf, Tjip S / Migliori, Giovanni B / Alffenaar, Jan-Willem C

    International journal of antimicrobial agents

    2017  Volume 49, Issue 6, Page(s) 688–694

    Abstract: Linezolid is used increasingly for the treatment of multi-drug-resistant (MDR) and extensively-drug-resistant (XDR) tuberculosis (TB). However, linezolid can cause severe adverse events, such as peripheral and optical neuropathy or thrombocytopenia ... ...

    Abstract Linezolid is used increasingly for the treatment of multi-drug-resistant (MDR) and extensively-drug-resistant (XDR) tuberculosis (TB). However, linezolid can cause severe adverse events, such as peripheral and optical neuropathy or thrombocytopenia related to higher drug exposure. This study aimed to develop a population pharmacokinetic model to predict the area under the concentration curve (AUC) for linezolid using a limited number of blood samples. Data from patients with MDR-/XDR-TB who received linezolid and therapeutic drug monitoring as part of their TB treatment were used. Mw\Pharm 3.82 (Mediware, Zuidhorn, The Netherlands) was used to develop a population pharmacokinetic model and limited sampling strategy (LSS) for linezolid. LSS was evaluated over a time span of 6 h. Blood sampling directly before linezolid administration and 2 h after linezolid administration were considered to be the most clinically relevant sampling points. The model and LSS were evaluated by analysing the correlation between AUC
    Language English
    Publishing date 2017-06
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2017.01.017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top